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IndependentModulation of Engagement and Connectivity
of the Facial Network During Affect Processing by CACNA1C
andANK3 Risk Genes for Bipolar Disorder
Danai Dima, PhD; Jigar Jogia, PhD; David Collier, PhD; Evangelos Vassos, MD, PhD; Katherine E. Burdick, PhD;
Sophia Frangou, MD, PhD
B ipolar disorder (BD) is characterizedbymooddysregu-lation and a typically remitting-relapsing course.1 Ge-nome-wide association studies (GWASs) have success-
fully identified several common risk-conferring variants,
includingmarkerswithin theCACNA1C (HGNC1390)andANK3
(HGNC 494) genes.2,3
The CACNA1C gene encodes the alpha subunit of the
L-type voltage-dependent calcium (Ca+2) channel Cav1.2.
These channels mediate the influx of Ca+2 on membrane
polarization, thus influencing neuronal ability to generate
and transmit electrical signals.4 In addition, the L-type Ca+2
channel subunit Cav1.2 contributes to the development and
maturation of parvalbumin (PV) γ-aminobutyric acid–
transmitting (GABAergic) interneurons.5 The ANK3 gene en-
codes ankyrin G, a cytoskeletal scaffolding protein located in
the axon initial segment of neurons and in the nodes of
Ranvier.6AnkyrinGdeterminesactionpotential generationby
the cooperative activation of sodium gated channels at the
nodes of Ranvier7 and promotes the formation of GABAergic
synapses at the axon initial segment.8 Of particular interest
from the perspective of the neural systems is the link be-
tween CACNA1C and ANK3 and the GABAergic interneurons.
Brain oscillatory activity, considered a hallmark of neuronal
network function,9 cruciallydependsonGABAergic function.10
IMPORTANCE Genome-wide association studies (GWASs) indicate that single-nucleotide
polymorphisms in the CACNA1C and ANK3 genes increase the risk for bipolar disorder (BD).
The genes influence neuronal firing bymodulating calcium and sodium channel functions,
respectively. Both genes modulate γ-aminobutyric acid–transmitting interneuron function
and can thus affect brain regional activation and interregional connectivity.
OBJECTIVE To determine whether the genetic risk for BD associated with 2 GWAS-supported
risk single-nucleotide polymorphisms at CACNA1C rs1006737 and ANK3 rs10994336 is
mediated through changes in regional activation and interregional connectivity of the facial
affect–processing network.
DESIGN, SETTING, AND PARTICIPANTS Cross-sectional functional magnetic resonance imaging
study at a research institute of 41 euthymic patients with BD and 46 healthy participants, all
of British white descent.
MAIN OUTCOMES ANDMEASURES Blood oxygen level–dependent signal and effective
connectivity measures during the facial affect–processing task.
RESULTS In healthy carriers, both genetic risk variants were independently associated with
increased regional engagement throughout the facial affect–processing network and
increased effective connectivity between the visual and ventral prefrontal cortical regions. In
contrast, BD carriers of either genetic risk variant exhibited pronounced reduction in ventral
prefrontal cortical activation and visual-prefrontal effective connectivity.
CONCLUSIONS AND RELEVANCE Our data demonstrate that the effect of CACNA1C rs1006737
and ANK3 rs10994336 (or genetic variants in linkage disequilibrium) on the brain converges
on the neural circuitry involved in affect processing and provides a mechanism linking BD to
genome-wide genetic risk variants.
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Thus,CACNA1C andANK3may independently influenceneu-
ronal firing and coupling.
Functional magnetic resonance imaging (fMRI) studies
have begun touncover the effects of risk variants inCACNA1C
andANK3at theneural systemlevel inhealthy individuals.Re-
search to date has focused on GWAS-supported single-
nucleotidepolymorphismsatCACNA1C rs1006737 (signalmaxi-
mumat rs1006737;P = 7.0 × 10−8) andANK3 rs10994336 (signal
maximum at rs10994336; P = 9.1 × 10−9).2,3 Although in-
tronic, these single-nucleotide polymorphisms are associ-
atedwithalteredgeneexpression inthebrain.11,12TheCACNA1C
rs1006737 risk allele has been associated with overactivation
of the amygdala (AMG)–hippocampal complex and the pre-
frontal cortex during cognitive and affect-processing
tasks.11,13-15 In addition, theCACNA1C rs1006737 risk allele in-
fluencesconnectivitybetweentherightandlefthippocampus16
andbetween theprefrontal cortex and theAMG17 and subcor-
tical regions.18 Genetic variation in ANK3may also influence
prefrontal function19andoccipital-prefrontal coupling.20These
functional changes in the brainmayunderpin the association
between either risk allele and increased behavioral reactivity
tonegative affective stimuli.21 Therefore,CACNA1C andANK3
riskallelesmayberelevant to reportsofdisease-associateddys-
function in engagement and connectivity betweenprefrontal
regions with limbic22-30 and occipital areas.31
In this study, we combined conventional Statistical Para-
metricMapping (SPM) anddynamic causalmodeling (DCM)32
of fMRIdata todefine the functional consequences in thebrain
ofCACNA1C rs1006737andANK3 rs10994336duringaffectpro-
cessing in euthymic patients with BD comparedwith healthy
individuals. Facial affect is processed mainly in a right-sided
networkthat involvesoccipitalandtemporal regionsof theven-
tral visual pathway within the inferior occipital gyrus (IOG),
fusiform gyrus (FG), AMG, and ventral prefrontal cortex
(VPFC).33-35 We focused on this network primarily because it
overlapswith regions implicated inBD.36Moreover, initial re-
ports have confirmed that at least 1 of the risk alleles of inter-
est,CACNA1C rs1006737, is functionalwithin this network; in
patientswithBD, thepresenceof this risk allele amplifies fron-
tolimbic abnormalities during facial affect processing.15,18
Basedon this evidence,we tested thehypothesis thatdur-
ing facial affect processing, CACNA1C rs1006737 and ANK3
rs10994336 riskvariantswill independentlyact to increasedis-
ease-related abnormalities in activation andeffective connec-
tivity within the facial affect–processing network. Specifi-
cally, we hypothesized that in patients with BD, the presence
of either risk allelewill increase neural responses in posterior
facial affect–processingnetworkregionswhileexacerbatingab-
normalities in activation and connectivity in ventral prefron-
tal regions.
Methods
Participants
Eighty-seven participants of self-reported white British an-
cestrywere identified throughdepartmental databases aspart
ofongoing studieson thepathophysiologyofBD.Details of the
sampleassessmentareprovided in theonlinematerial (Supple-
ment [eMethods]). Forty-one euthymic patients with bipolar
I disorder, diagnosed according to DSM-IV criteria,1 were in-
cluded inthestudy.Forty-sixhealthy individualswithoutaper-
sonal or a family history of Axis I DSM-IV disorders and
matched to the patients on age, sex, and IQ (measured using
the Wechsler Adult Intelligence Scale–Revised37) were se-
lected as a control group. All participants underwent screen-
ing to exclude past, present, and hereditary medical disor-
ders; DSM-IV lifetime alcohol or other drug dependence;
alcoholorotherdrugabuse in thepreceding6months;andcon-
traindications toMRI.Psychopathologywasassessedusing the
Hamilton Depression Rating Scale,38 the YoungMania Rating
Scale,39 and the Brief Psychiatric Rating Scale (BPRS).40
The study was approved by the Joint South London and
Maudsley and Institute of Psychiatry research ethics commit-
tee. All participants provided written informed consent be-
fore study participation.
DNA Extraction and Genotyping
WeobtainedDNAfromtheparticipantsusingbuccal swabsand
conventional procedures. The CACNA1C (rs1006737; risk al-
leleA) andANK3 (rs10994336; risk alleleT) genotypeswerede-
termined by an allelic discrimination assay (TaqMan Assay
C_31344821_10; Applied Biosystems). End-point analysis was
performed using fast real-time polymerase chain reaction
analysis (7900HT;AppliedBiosystems).Genotypeswerecalled
with the manufacturer’s software (SDS, version 2.3; Applied
Biosystems), and the output was checked visually to ensure
genotypes fell intodistinct clusters. The call ratewas 100%be-
cause buccal swabswere repeated for 7 individuals forwhom
initial genotyping results were undetermined. Accuracy was
assessed by duplicating 15% of the sample, and reproducibil-
ity was 100%.
Facial Affect Paradigm
The paradigm included 3 negative facial emotions (fear, an-
ger, and sadness) in 3 separate experiments conducted in a
single acquisition session in a randomized order. This para-
digmconsistedof 3 event-related tasks lasting 5minutes each.
In each task, 10 different facial identities (http://paulekman
.com/) depicting 150% intensity of a negative (fear, anger, or
sadness)oraneutral facialexpressionwerepresented inapseu-
dorandomorder interspersedwith a fixation cross. The 150%
level of intensitywas chosen tominimize ambiguity about the
nature of the stimuli. The stimuli (affective and neutral faces
and the fixation cross) were each displayed for 2 seconds and
repeated 20 times. The interstimulus interval followedaPois-
son distribution and varied between 3 and 9 (mean interval,
5) seconds. Participants were instructed to press the right or
the left button with their dominant hand on an MRI-
compatible response box to indicate whether the face had an
emotional or a neutral expression. Response time and accu-
racy data were collected.
Image Acquisition
Anatomical and functional imaging data were acquired dur-
ing the samesessionusing a 1.5-TMRI system (GESigma;Gen-
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eral Electric). Gradient-echo planarmagnetic resonance (MR)
images were acquired at each of the 16 noncontiguous
planes paral lel to the intercommissural (anterior
commissure–posterior commissure) plane. We acquired T2*-
weighted MR images reporting blood oxygenation level–
dependent contrast (repetition time, 2000 milliseconds;
echo time, 40 milliseconds; flip angle, 70°; section thick-
ness, 7 mm; section skip, 0.7 mm; matrix size, 64 × 64;
voxel dimensions, 3.75 × 3.75 × 7.7 mm). For each partici-
pant, 450 fMRIs were acquired. A high-resolution
T1-weighted structural image was acquired in the axial
plane for coregistration (inversion recovery-prepared,
spoiled gradient-echo sequence; repetition time, 18 milli-
seconds; echo time, 5.1 milliseconds; inversion time, 450
milliseconds; flip angle, 20°; slice thickness, 1.5 mm; matrix
size, 256 × 192; field of view, 240 × 180 mm; voxel dimen-
sions, 0.9375 × 0.9375 × 1.5 mm; number of excitations, 1).
Statistical Parametric Mapping
Data analysis was implemented using SPM8 (www.fil.ion.ucl
.ac.uk/spm/; Wellcome Trust Centre for Neuroimaging). Pre-
processing involved spatial transformations (realignment and
transformation into standard stereotacticMontrealNeurologi-
cal Institute space using the participants’ anatomical image)
and smoothingwith an isotropic gaussiankernel of 8mmfull-
widthhalfmaximum.Foreachparticipant, the fMRIdata from
the 3 event-related tasks (fear, anger, or sadness vs neutral)
were concatenated and modeled with a general linear (con-
volution) model. Vectors of onset representing correct re-
sponses were convolved with a canonical hemodynamic re-
sponse function. Sixmovementparameterswere also entered
as nuisance covariates. Themeans of the 3 sessionswere also
modeled, as was the transition at the end of each session. For
eachparticipant, contrast images (affective > neutral facial ex-
pressions) were produced.
Group-level analyseswerebasedonrandom-effects analy-
ses of the single-subject contrast images using the summary
statistic approach.Datawereanalyzedusing2approaches. For
each genetic variant, the primary hypothesis-testing analy-
ses focused on the effect of the diagnosis, the genotype, and
their interaction within volumes of interest (VOIs) defined
within the facial affect–processingnetwork, followedbywhole-
brain analyses to test for significant main effects or interac-
tions outside the predefined areas.
Based on previous work from our laboratory,35 we se-
lectedVOIswithin the IOG,FG,AMG, andVPFC,whichare the
keybrain regionsengaged in facialprocessing.TheseVOIswere
defined using a mask derived from the automated anatomi-
cal labeling atlas inWake Forest University PickAtlas (version
3.0.3; www.fmri.wfubmc.edu/software/PickAtlas).
For the VOI and whole-brain analyses, statistical infer-
ence was based on a threshold of P < .001, uncorrected, with
avoxelwise extent thresholdof k = 20; in addition, for theVOI
analysis, a small-volume correction was applied (VOI radius,
10 [measured as percentage of change inBOLDsignal];P < .05
at cluster level, familywise error).41 We used response times
andtheBPRS total scoreascovariates inall analyses.TheBPRS,
Hamilton Depression Rating Scale, and Young Mania Rating
Scalescoreswerehighlycorrelated(forall,R > 0.82[P > .0001]).
To avoid collinearity, we used the total BPRS score as a covar-
iate because, unlike the other scales, it is applicable to non-
clinical populations. In the BPRS, symptoms are rated from 1
(absent) to 7 (extremely severe), with ratings below 4 corre-
sponding to nonpathological experiences.
Measures of brain activation (weighted parameter
estimates)42were extracted for eachVOI from1-sample t tests
(contrast imagesaffective > neutral facial expressions) foreach
diagnostic group using a region-of-interest toolbox for SPM
(MarsBaR; http://marsbar.sourceforge.net). These measures
were imported in commercially available software (SPSS, ver-
sion 17; SPSS, Inc) to examine their association with task per-
formance and with medication type and dose on the day of
scanning.
Dynamic Causal Modeling
Dynamic causal modeling32 is a Bayesian model comparison
procedure that estimates directed interactions within neural
systems. Crucially, DCM models these neural interactions
and distinguishes between endogenous and context-
specific coupling while accounting for the effects of experi-
mentally controlled network perturbations (in contrast to
stimulus-locked coupling).32,43 In the previous study from
our laboratory,35 the strategy for determining the most par-
simonious model for facial affect processing was detailed.
In summary, a 4-area DCM was defined for all participants
with endogenous connections between VOIs specified in
the IOG, FG, AMG, and VPFC, with the main effect of all
faces as the driving input to the IOG. We then produced and
tested 7 models that included all possible permutations
regarding how facial affect (fear, anger, or sadness) could
modulate connections within the network (Supplement
[eFigure]).
Model comparison was implemented using random-
effects Bayesian model selection in DCM8 to compute ex-
ceedance andposterior probabilities at the group level44 sepa-
rately for controls and patients with BD. The exceedance
probability of a givenmodel denotes the probability that this
model ismore likely than any othermodel tested. To produce
quantitative measures of the strength of effective connectiv-
ityand itsmodulation,weusedrandom-effectsBayesianmodel
averaging toobtainmeanconnectivity estimates (weightedby
their posterior model probability) across all models and all
subjects.45 Once the optimalmodels for controls and patients
weredetermined,we tested themodulationof themodel con-
nections by each of the risk variants separately in SPSS, ver-
sion17,using2-sample t testsornonparametric testswhendata
were not normally distributed based on the Kolmogorov-
Smirnov criterion, with α = .05.
Results
Participants
Demographic and Clinical Data
Results for the CACNA1C rs1006737 (risk allele A) are shown
inTable 1. Individualswith theCACNA1CAA allele (5 patients
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Table 2. Demographic and Clinical Characteristics of the Study Participants by Diagnosis, ANK3Genotype (rs10994336; Risk Allele T), and
Diagnosis×Genotype Interactiona
Characteristic
Effect of Diagnosis Effect of ANK3 Genotype Diagnosis × Genotype Interaction
BD Patients
(n = 41)
Controls
(n = 46)
TT+CT
(n = 30)
CC
(n = 57)
BD Patients
With TT+CT
(n = 16)
Controls With
TT+CT
(n = 14)
BD Patients
With CC
(n = 25)
Controls With
CC
(n = 32)
Age, y 44.3 (11.9) 40.3 (13.2) 42.3 (13.0) 38.5 (13.4) 42.0 (10.7) 40.6 (12.2) 43.3 (12.3) 39.3 (12.3)
Sex, No. of
Participants
Male 20 25 17 27 9 7 11 18
Female 21 21 13 30 7 7 14 14
Educational level 3.5 (1.0) 3.6 (1.0) 3.5 (1.0) 3.5 (0.9) 3.5 (0.9) 4.2 (0.8) 3.1 (0.8) 3.6 (1.0)
IQ 117.9 (17.9) 112.6 (14.5) 121.7 (16.3) 111.8 (15.8) 112.3 (16.2) 110.7 (12.9) 121.7 (16.3) 116.7 (14.5)
HDRS total scoreb,c 4.8 (5.3) 0.1 (0.5) 2.9 (4.8) 0.5 (0.9) 5.3 (4.6) 0.4 (0.9) 1.5 (0.9) 0.1 (0.4)
YMRS total scorec,b 1.4 (3.0) 0.2 (0.6) 0.8 (2.2) 0.1 (0.3) 1.6 (2.9) 0.2 (0.4) 0.7 (1.4) 0.2 (0.6)
BPRS total scoreb,c 27.5 (4.0) 24.3 (0.7) 26.2 (3.7) 24.6 (1.0) 27.3 (4.3) 24.8 (1.1) 25.9 (1.9) 24.2 (0.6)
Age at onset, y 24.7 (8.0) … … … 23.3 (7.7) … 21.5 (7.2) …
Duration of illness, y 20.2 (10.5) … … … 22.6 (9.0) … 16.3 (10.7) …
No. of depressive
episodes
5.7 (7.5) … … … 11.3 (14.0) … 4.2 (3.8) …
No. of manic
episodes
5.6 (7.7) … … … 12.2 (16.2) … 3.7 (2.8) …
Correctly identified
faces, %
90.3 (4.1) 93.1 (4.8) 92.7 (5.9) 91.4 (8.3) 91.2 (6.2) 95.0 (4.1) 90.0 (9.4) 92.8 (7.0)
Response time, msb 1491 (209) 1109 (241) 1223 (260) 1165 (231) 1244 (221) 1193 (328) 1252 (249) 1096 (185)
Abbreviations: BD, bipolar disorder; BPRS, Brief Psychiatric Rating Scale;
ellipses, not applicable; HDRS, Hamilton Depression Rating Scale; YMRS, Young
Mania Rating Scale.
a Unless otherwise indicated, data are expressed as mean (SD).
b Scores for BD patients are significantly greater than those for controls
(P < .02).
c Scores for BD patients in the CT+TT group are significantly greater than those
for all other groups (P < .02).
Table 1. Demographic and Clinical Characteristics of the Study Participants by Diagnosis, CACNA1CGenotype (rs1006737; Risk Allele A), and
Diagnosis×Genotype Interactiona
Characteristic
Effect of Diagnosis Effect of CACNA1C Genotype Diagnosis × Genotype Interaction
BD Patients
(n = 41)
Controls
(n = 46)
AA+AG
(n = 42)
GG
(n = 45)
BD Patients
With AA+AG
(n = 17)
Controls With
AA+AG
(n = 25)
BD Patients
With GG
(n = 24)
Controls With
GG
(n = 21)
Age, y 44.3 (11.9) 40.3 (13.2) 40.1 (11.1) 39.5 (12.4) 44.4 (12.3) 36.3 (10.4) 44.1 (11.6) 38.1 (13.4)
Sex, No. of
participants
Male 20 25 21 24 6 16 14 12
Female 21 21 21 21 11 9 10 9
Educational level 3.5 (1.0) 3.6 (1.0) 3.8 (0.9) 3.3 (1.0) 3.6 (0.9) 3.9 (0.9) 3.2 (1.0) 3.4 (1.0)
IQ 117.9 (17.9) 112.6 (14.5) 113.6 (18.4) 114.4 (13.0) 118.7 (20.2) 101.5 (12.5) 116.9 (14.5) 111.8 (17.2)
HDRS total scoreb,c 4.8 (5.3) 0.1 (0.5) 2.0 (3.5) 3.2 (5.5) 6.8 (6.5) 0.1 (0.5) 3.3 (3.8) 0.1 (0.5)
YMRS total scoreb,c 1.4 (3.0) 0.2 (0.6) 0.3 (0.7) 1.1 (2.7) 2.4 (3.5) 0.3 (0.6) 0.8 (2.3) 0.1 (0.7)
BPRS total scoreb,c 27.5 (4.0) 24.3 (0.7) 25.4 (2.1) 26.4 (4.2) 29.1 (5.0) 24.4 (0.7) 26.3 (2.6) 24.2 (0.6)
Age at onset, y 24.7 (8.0) … … … 26.4 (9.3) … 22.2 (4.7) …
Duration of illness, y 20.2 (10.5) … … … 19.0 (11.1) … 21.9 (9.7) …
No. of depressive
episodes
5.7 (7.5) … … … 4.7 (3.7) … 7.9 (12.1) …
No. of manic episodes 5.6 (7.7) … … … 4.0 (3.5) … 8.2 (11.5) …
Correctly identified
faces, %
90.3 (4.1) 93.1 (4.8) 91.7 (7.7) 91.7 (7.8) 90.9 (7.9) 92.9 (6.5) 89.4 (8.8) 93.3 (6.6)
Response time, msb 1491 (209) 1109 (241) 1189 (267) 1171 (200) 1240 (249) 1125 (285) 1265 (236) 1097 (128)
Abbreviations: BD, bipolar disorder; BPRS, Brief Psychiatric Rating Scale;
ellipses, not applicable; HDRS, Hamilton Depression Rating Scale; YMRS, Young
Mania Rating Scale.
a Unless otherwise indicated, data are expressed as mean (SD).
b Scores for BD patients are significantly greater than those for controls
(P < .02).
c Scores for BD patients in the AA+AG group are significantly greater than those
for all other groups (P < .03).
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withBDand4controls)were considered togetherwithAGhet-
erozygotes (19 patients with BD and 17 controls) within each
diagnostic group. Results for theANK3 rs10994336 (risk allele
T) are presented in Table 2. Because of the rarity of the risk
T allele (HapMap CEU minor allele frequency, 0.07; www
.hapmap.org), individuals with TT (2 patients with BD and 1
control) and CT (14 patients with BD and 13 controls) alleles
were considered together within each diagnostic group.
We found no effect of either genotype or of the geno-
type × diagnosis interaction on demographic data (P > .11)
or on clinical variables (P > .29) except for BD carriers of the
CACNA1C or ANK3 risk allele who had higher symptom
scores compared with all other groups (P < .02). Similar
behavioral changes have been observed in healthy carriers
of either risk allele who report higher ratings of anxiety,
anhedonia, and neuroticism.16,21
Task Performance
Details are shown inTables 1 and 2. No significant effect of di-
agnosis, genotype, or their interactionwas observed for accu-
racy (P > .63). Patients had longermean response times com-
pared with the controls, but no effect of genotype or of a
genotype × diagnosis interaction was detected (P > .56).
Statistical Parametric Mapping
Processing of affective compared with neutral facial expres-
sionswasassociatedwithenhancedactivation throughout the
relevant network in both diagnostic groups (Supplement
[eTable]).However, comparedwith controls, patientswithBD
(regardless of genotype) showed reduced activation in the vi-
sual cortex (IOG), temporal visual association cortex (FG), and
the VPFC. The CACNA1C andANK3 risk alleles were indepen-
dently associatedwith increasedactivation in the IOG,FG, and
AMGinall participants regardlessofdiagnosis (Figure 1). A sig-
nificant diagnosis × genotype interaction was noted in the
VPFC. The presence of either risk allele was associated with
increased VPFC activation in controls but reduced VPFC acti-
vation in patientswith BD (Figure 1). Themain effect of geno-
type and thegenotype × diagnosis interactionobserved in the
VOI analyses remained significant in thewhole-brain volume
analyses.The latteranalyses identified further regionswithsig-
nificant effect of genotype in the angular gyrus (x = −30,
y = −54, z = 34 [z score, 3.34]) for carriers of theCACNA1C risk
allele and the middle occipital gyrus (left: x = −26, y = −90,
z = −4 [z score, 3.70]; right: x = 48, y = −66, z = −14 [z score,
3.68]) for carriers of the ANK3 risk allele.
Dynamic Causal Modeling
Results are presented in Figure 2. For simplicity, we used a
single modulatory term labeled facial affect. The models
contain distinct modulatory inputs for fear, anger, and sad-
ness, allowing us to test their individual influence on
connectivity.
In the controls, we replicated the previous finding35 that
the optimal model for facial processing with an exceedance
probability of 41% contains reciprocal connections among all
4 network areas (IOG, FG, AMG, andVPFC). Affect processing
(regardless of valence or genotype) was associated with sig-
Figure 1. Effect of Bipolar Disorder (BD) Risk Genes on Facial Affect Processing
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The effect of CACNA1C rs1006737
and ANK3 rs10994336 risk variants
on the inferior occipital gyrus (IOG),
fusiform gyrus (FG), amygdala (AMG),
and ventral prefrontal cortex (VPFC)
function during facial affect
processing in patients with BD and
healthy controls (HC) in mean signal
intensity (reported as a percentage of
whole-brain volume signal change).
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nificantly increased modulation of the forward connection
from the IOG to the VPFC (Figure 2A and Supplement [eFig-
ure, model 1]). In the controls, the presence of the CACNA1C
(P = .02) and ANK3 (P = .04) risk alleles further increased ef-
fective connectivity between these regions (Figure 2B).
In the patients with BD, as in the controls, the optimal
model with an exceedance probability of 32% also contained
reciprocal connections among all 4 network areas (IOG, FG,
AMG, and VPFC). Affect processing (regardless of valence or
genotype)was associatedwith reducedvisual-prefrontal con-
nectivity coupled with increased modulation in the forward
connection from theAMG to theVPFC (Figure 2A andSupple-
ment [eFigure, model 3]). Moreover, BD carriers of the
CACNA1C (P = .02)orANK3 (P = .04) riskvariant expressed fur-
ther reductions in connectivity from the IOG to the VPFC
(Figure 2B).
Differences between the 2 diagnostic groups were noted
in themodulation by facial affect of the IOG to VPFC (P = .02)
and AMG to VPFC (P = .03) connections. Furthermore, the
genotype × group interaction for the IOG toVPFC connection
was statistically significant for the CACNA1C (P = .003) and
ANK3 (P = .01) genotypes.
No significant effect ofmedicationwas found inanyof the
analyses. Inaddition,nosignificant correlationbetweenmedi-
cation dose and any brain activation or connectivity param-
eters (P > .42) was found.
Discussion
We used SPM and DCM to investigate the effect of CACNA1C
and ANK3 GWAS-supported risk variants on regional activa-
tion and interregional connectivity during facial affect pro-
cessing in healthy controls comparedwith euthymic patients
with BD. We found that both genetic risk variants were inde-
pendentlyassociatedwith (1) increasedengagement in theven-
tral visual pathway and in the AMG irrespective of diagnosis,
(2) increased VPFC activation and visual-prefrontal effective
connectivity in controls, and (3) increased deviance in ven-
tral prefrontal activation and visual-prefrontal effective con-
nectivity in patients with BD.
The Effect of CACNA1C andANK3Variation on the Facial
Affect–Processing Network in Controls
Asexpected,35,46 facial affectprocessingenhanced regional ac-
tivationwithin the correspondingnetwork regardless of geno-
type. The presence of either risk allele amplified these affect-
related neural responses. This genotype effect has been
reported previously in the AMG14,15 and VPFC15 for CACNA1C
rs1006737. Our study suggests that genetic modulation of re-
gional activation by CACNA1C rs1006737 within this network
is not limited to frontolimbic regions but extends to the ven-
tral visual pathway (IOG and FG). A similar pattern of affect-
related overactivation throughout the facial-processing net-
workwas also present inANK3 rs10994336 risk allele carriers.
Regardless of genotype, optimal processing of visual
stimuli depends on visual-prefrontal cortical coupling. Spe-
cifically, visual cortical areas in the IOG rapidly project par-
tially analyzed information directly to the VPFC; this coarse
representation subsequently triggers predictions within
temporal regions (FG and AMG) about the most likely inter-
Figure 2. Results of Dynamic Causal Modeling (DCM) and Bayesian
Model Averaging in Healthy Controls and PatientsWith Bipolar Disorder
(BD)
A
Controls
Optimal Model
VPFC
IOG
All faces
AMG
FG
BD Patients
Optimal Model
VPFC
IOG
All faces
AMG
FG
B
Controls
CACNA1C rs1006737
VPFC
IOG
All faces
AMG
FG
BD Patients
CACNA1C rs1006737
VPFC
IOG
All faces
AMG
FG
Controls
ANK3 rs10994336
VPFC
IOG
All faces
AMG
FG
BD Patients
ANK3 rs10994336
VPFC
IOG
All faces
AMG
FG
A, Optimal DCM selection. Models compromised by a 4-area DCM are specified
with bidirectional endogenous connections among all regions (inferior occipital
gyrus [IOG], fusiform gyrus [FG], amygdala [AMG], and ventral prefrontal cortex
[VPFC]) and a driving input of all faces into the IOG. For ease of display, affect
modulations are labeled as facial affect (black dot) but correspond to the
distinct modulations of fearful, angry, and sad faces. B, Alterations in effective
connectivity within the facial processing network established by Bayesian
model averaging across all models considered. For controls, the bold black
arrows indicate significantly increased connectivity from the IOG to the VPFC
modulated by the CACNA1C (rs1006737) and ANK3 (rs10994336) risk variants.
For patients with BD, the dashed arrows indicate significantly decreased
connectivity from the IOG to the VPFCmodulated by the CACNA1C (rs1006737)
and ANK3 (rs10994336) risk variants. Black solid arrows indicate all other
network connections.
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pretations of the stimulus.47-49 When visual stimuli include
affective information, this early visual-prefrontal coupling is
further increased.50 Accordingly, we found a robust modula-
tion of effective connectivity between the IOG and VPFC by
facial affect that was further enhanced in carriers of the
CACNA1C rs1006737 or the ANK3 rs10994336 risk allele.
Therefore, one could argue that neural overresponsiveness to
affective information could represent a common biological
pathway shared by these 2 risk-conferring single-nucleotide
polymorphisms for BD. This notion is further supported by
neurophysiological evidence showing greater startle
reactivity,21 indicating increased neuronal excitability, in
healthy carriers of either risk allele.
Although the underlying molecular mechanisms are
beyond the resolution of neuroimaging, we hypothesize
that the neurogenetic effects of either risk allele are medi-
ated through changes in brain oscillatory activity. The func-
tional coupling of visual and prefrontal cortices during
visual processing relies on synchronized long-range oscilla-
tions within the gamma frequency band.10,51 Recent optoge-
netic experiments have confirmed that gamma oscillations
originate from PV-GABAergic interneurons following excit-
atory input from pyramidal cells.10 The CACNA1C and ANK3
genes are known to modulate neuronal firing, signaling, and
PV-interneuron function, which are pertinent to the genera-
tion of gamma oscillations4,5,7,8 and offer a plausible link
between the molecular properties of the genes and their
putative system-level effects observed here.
Effect of CACNA1C andANK3Variation on the Facial
Affect–Processing Network in BD
Regardless of genotype, patients with BD showed VPFC hy-
poactivation, consistentwithprevious reports.26,27,52 This ab-
normality was exacerbated in BD carriers of either risk allele.
In all other network regions, the presence of either risk allele
amplified affect-related neural responses. This genotype-
related imbalance inengagementbetweenposterior facial net-
work regions and theVPFChas been previously described for
CACNA1C rs1006737.15Our findings suggest a similar effect for
the ANK3 rs10994336 risk allele.
Regardless of genotype, thepatientswithBD showedevi-
dence of significant reduction in visual-prefrontal cortical ef-
fective connectivity but increased forward connectivity be-
tween the AMG andVPFC comparedwith the controls. These
findings confirm previous reports of increased AMG-
prefrontal coupling inBD22-30 andprovidenewevidenceof vi-
sual-prefrontal reduction in effective coupling. The latterwas
affected by CACNA1C and ANK3 variation because BD carri-
ers of either risk allele show greater dysfunction. Several re-
ports have foundabnormalneuronal synchronization inBD in
the long-rangegammabandduringmultiple tasks,53-55 includ-
ing facial affect processing,56 that provides aplausiblemecha-
nistic explanation for the observed reduction in visual-
prefrontal cortical connectivity in BD.
Central Role of VPFC Dysfunction in the Pathophysiology
of BD
Our results also strengthen the case forVPFCpathology in the
pathogenesis of BD.57 Postmortem studies in BD report neu-
ropathological abnormalities in the VPFC, leading to regional
reductions in the number and density of pyramidal cells and
PV interneurons.58,59 Themechanisms involvedarenot estab-
lished, but multiple lines of evidence implicate reduced ex-
pression of neurotrophins,60 abnormalities in oxidative en-
ergy generation,60,61 andmitochondrial dysfunction resulting
in altered Ca+2 regulation60 and PV-interneuron reduction.62
Given the known properties of the CACNA1C and ANK3 risk
alleles discussed here, we postulate that the risk alleles may
further reduce the integrity of the interactions between excit-
atory signals from pyramidal neurons and inhibition by
GABAergic interneurons.10,63 Amore precise formulation of a
pathophysiologicalmodel for BD crucially depends on the fu-
ture availability of data directly testing these predictions.
Methodological Considerations
Several methodological issues require further consideration.
First, possiblemedication effects on the study results cannot
be conclusively refuted.However,we foundno significant re-
lationship between medication and measures of regional ac-
tivation or effective connectivity. Second, we did not test for
epistatic effects because the number of individuals carrying
both risk variants was small (3 patients and 3 controls). This
finding is expected, given the rarity of the ANK3 risk allele.
However,Moskvinaandcolleagues64 foundnoconvincingevi-
dence of epistasis between the GWAS-supported single-
nucleotidepolymorphisms inANK3 andCACNA1C in theWell-
comeTrustCaseControl Consortiumdata (1868 caseswithBD
and2938 controls). They suggested thatGWAS-supported loci
maybedetectable because theydonot require interactions to
exert an effect. Finally, the absence of a diagnosis or a geno-
type effect on task performance is a particular strength of the
study and confirms the increased assay sensitivity of neuro-
imaging in uncovering the neural correlates of diagnostic and
genetic variability. Thegenetic risk factors examinedhere and
the results obtained show at least partial overlap with find-
ings in other disorders, primarily schizophrenia.59,65 This ob-
servation adds to accumulating evidence that the diagnostic
categoriesused inclinicalpracticeareunlikely to representun-
derlying genetic and pathophysiological risk accurately.
In summary,we demonstrated that the effect ofCACNA1C
rs1006737 andANK3 rs10994336 (or genetic variants in linkage
disequilibrium) on the brain converges on neural circuitry in-
volved in facial affect processing. Thus, we provide a mecha-
nism linking BDwith genome-wide genetic risk variants.
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